Moderna stock surged Thursday after the Covid vaccine-maker significantly cut its third-quarter costs, and still managed to ...

Moderna stock is trading sharply lower Monday afternoon as recent clinical setbacks overshadowed positive pipeline news.

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

Moderna’s stock narrative has experienced a notable shift following recent analyst updates. The consensus fair value is ...

Moderna's shares have been southbound for the past few years due to unimpressive financial results. However, progress with the pipeline could significantly boost the stock over the next five years.

Moderna (MRNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate ...

Moderna beat analysts’ revenue expectations by 10.7% last quarter, reporting revenues of $142 million, down 41.1% year on ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report)’s stock price was down 5.2% during trading on Monday after Leerink Partners lowered their price target on the stock from $18.00 to $15.00. Leerink ...

Learn more about whether Moderna, Inc. or Viridian Therapeutics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

In the short term, Moderna (NASDAQ: MRNA) looks like a bad bet. It's coming off of the momentum of its COVID-19 vaccine, and doesn't have a lot of new ammo ready yet to expand in new directions. I ...

Versant Capital Management Inc grew its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 408.9% in the first quarter, according to the company in its most recent disclosure with the SEC. The ...